Statin Therapy Is Associated with Reduced Risk of Peptic Ulcer Disease in the Taiwanese Population

Lin, Chun Jung; Liao, Wei; Chen, Yu An; Lin, Hwai Jeng; Feng, Chun; Lin, Cheng Li; Lin, Ying; Kao, Min Chuan; Huang, Mei; Lai, Chih Ho; Kao, Chia Hung

doi:10.3389/fphar.2017.00210

Cited by 22 publications

(18 citation statements)

References 34 publications

(50 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We have recently reported that high serum cholesterol levels in humans leads to an increased risk of being infected with H. pylori and induction of pathogenesis [35,50]. A population-based case-control study revealed that in patients who were prescribed statins (cholesterol-lowering agents), there was a decrease in H. pylori infection, and a reduced risk of peptic ulcer disease and gastric cancer [51,52]. It has been reported that probiotics exhibit anti-obesity effects by lowering serum cholesterol [53,54].…”

Section: Discussionmentioning

confidence: 99%

Probiotic Lactobacillus spp. Act Against Helicobacter pylori-induced Inflammation

Chen

Tsai

et al. 2019

JCM

Self Cite

View full text Add to dashboard Cite

The bacterial species, Helicobacter pylori, is associated with several gastrointestinal diseases, and poses serious health threats owing to its resistance to antibiotics. Lactobacillus spp., on the other hand, possess probiotic activities that have beneficial effects in humans. However, the mechanisms by which Lactobacillus spp. harbor favorable functions and act against H. pylori infection remain to be explored. The aim of this study was to investigate the ability of bacterial strains, Lactobacillus rhamnosus and Lactobacillus acidophilus, termed GMNL-74 and GMNL-185, respectively, to inhibit H. pylori growth and inflammation. Our results showed that GMNL-74 and GMNL-185 possess potent antimicrobial activity against multidrug resistant (MDR)-H. pylori. In addition, an in vitro cell-based model revealed that the inhibition of H. pylori adhesion and invasion of gastric epithelial cells and interleukin-8 production were significantly decreased by treatment with both the Lactobacillus strains. In vivo studies demonstrated that colonization of H. pylori and induced inflammation in the mouse stomach were also alleviated by these Lactobacillus strains. Furthermore, the abundance of beneficial gut bacteria, including Bifidobacterium spp. and Akkermansia muciniphilia, were significantly increased in H. pylori-infected mice treated with GMNL-74 and GMNL-185. These results demonstrate that Lactobacillus spp. ameliorate H. pylori-induced inflammation and supports beneficial gut specific bacteria that act against H. pylori infection.

show abstract

Section: Discussionmentioning

confidence: 99%

Probiotic Lactobacillus spp. Act Against Helicobacter pylori-induced Inflammation

Chen

Tsai

et al. 2019

JCM

Self Cite

View full text Add to dashboard Cite

show abstract

“…It was found to enhance gastric mucosal defense against indomethacin-induced gastric ulceration via increasing NO and PGE 2 levels, promoting gastric mucin release and providing antioxidant activity [57]. Recent evidences concluded that statin mitigate Helicobacter pylori-associated pathogenesis [58] and protect against peptic ulcer in patients [59]. Neb has pleiotropic effects as being vasodilator and anti-oxidative which provides preferable protection from gastric ulcer [23].…”

Section: Discussionmentioning

confidence: 99%

Gastroprotective effects of nebivolol and simvastatin against cold restraint stress-induced gastric ulcer in rats

et al. 2020

View full text Add to dashboard Cite

Gastric ulcer is one of the most serious diseases. Nebivolol (Neb), a β1-blocker, exhibits vasodilator and antioxidative properties, simvastatin (Sim) antihyperlipidemic drug, exhibits anti-oxidative, anti-inflammatory properties and promote endogenous nitric oxide (NO) production. The aim of this study was to evaluate the gastroprotective effects of Neb and Sim against cold restraint stress (CRS)-induced gastric ulcer in rats. Rats were restrained, and maintained at 4°C for 3 hours. Animals were divided into six groups; control group, CRS group, and four treatment groups received ranitidine (Ran), Neb, Sim and both Neb and Sim. Treatments were given orally on a daily basis for 7 days prior to CRS. The gastroprotective effects of Neb and Sim were assessed biochemically by measuring variations in prostaglandins E2, NO, reduced glutathione and malondialdehyde, and functionally by estimating force of contractions of isolated rat fundus in the studied groups in response to acetylecholine stimulation and morphologically using hematoxylin and eosin staining, periodic acid Schiff 's reaction and immunohistochemistry for cyclooxygenase 2 in gastric mucosa. CRS caused significant ulcerogenic effect. Alternatively, pretreatment with Ran, Neb, and Sim significantly corrected biochemical findings, pharmacological and histological studies.

show abstract

“…The DDD, recommended by the World Health Organization (WHO), was assumed to be the average maintenance dose per day of a drug and analyzed as described previously ( Lin et al, 2017 ). The cumulative DDD was calculated by deriving the total prescribed DDD of each type of statin, namely simvastatin (ATC C10AA01) and lovastatin (ATC C10AA02), for statin users.…”

Section: Methodsmentioning

confidence: 99%

Simvastatin Therapy for Drug Repositioning to Reduce the Risk of Prostate Cancer Mortality in Patients With Hyperlipidemia

Chen

Lin

et al. 2018

Front. Pharmacol.

Self Cite

View full text Add to dashboard Cite

Prostate cancer (PCa) is one of the most commonly diagnosed cancers in the western world, and the mortality rate from PCa in Asia has been increasing recently. Statins are potent inhibitors of 3-hydroxy-3-methyl glutaryl coenzyme A (HMG-CoA) reductase and are commonly used for treating hyperlipidemia, with beneficial effects for cardiovascular disease and they also exhibit anti-cancer activity. However, the protective effects of statins against PCa are controversial. In this study, we investigated the effect of two types of statins (simvastatin and lovastatin) and the mortality rate of PCa patients by using the Taiwan National Health Insurance Research Database (NHIRD). A total of 15,264 PCa patients with hyperlipidemia records and medical claims from the Registry of Catastrophic Illness were enrolled. The patients were divided into two cohorts based on their statin use before the diagnosis of PCa: statin users (n = 1,827) and non-statin users (n = 1,826). The results showed that patients who used statins exhibited a significantly reduced risk of mortality from PCa [adjusted hazard ratio (HR) = 0.84, 95% CI = 0.73–0.97]. Analysis of the cumulative defined daily dose (DDD) indicated that patients who were prescribed simvastatin ≥ 180 DDD had a dramatically decreased risk of death from PCa (adjusted HR = 0.63; 95% CI = 0.51–0.77). This population-based cohort study demonstrated that statin use significantly decreased the mortality of PCa patients, and that this risk was inversely associated with the cumulative DDD of simvastatin therapy. The results of this study revealed that statins may be used for drug repositioning and in the development of a feasible approach to prevent death from PCa.

show abstract

Statin Therapy Is Associated with Reduced Risk of Peptic Ulcer Disease in the Taiwanese Population

Cited by 22 publications

References 34 publications

Probiotic Lactobacillus spp. Act Against Helicobacter pylori-induced Inflammation

Probiotic Lactobacillus spp. Act Against Helicobacter pylori-induced Inflammation

Gastroprotective effects of nebivolol and simvastatin against cold restraint stress-induced gastric ulcer in rats

Simvastatin Therapy for Drug Repositioning to Reduce the Risk of Prostate Cancer Mortality in Patients With Hyperlipidemia

Contact Info

Product

Resources

About